Abstract:Pompe disease is a lysosomal storage disorder that preferentially affects muscles, and it is caused by GAA mutation coding acid alpha‐glucosidase in lysosome and glycophagy deficiency. While the initial pathology of Pompe disease is glycogen accumulation in lysosomes, the special role of the lysosomal pathway in glycogen degradation is not fully understood. Hence, we investigated the characteristics of accumulated glycogen and the mechanism underlying glycophagy disturbance in Pompe disease. Skeletal muscle specimens were obtained from the affected sites of patients and mouse models with Pompe disease. Histological analysis, immunoblot analysis, immunofluorescence assay, and lysosome isolation were utilized to analyze the characteristics of accumulated glycogen. Cell culture, lentiviral infection, and the CRISPR/Cas9 approach were utilized to investigate the regulation of glycophagy accumulation. We demonstrated residual glycogen, which was distinguishable from mature glycogen by exposed glycogenin and more α‐amylase resistance, accumulated in the skeletal muscle of Pompe disease. Lysosome isolation revealed glycogen‐free glycogenin in wild type mouse lysosomes and variously sized glycogenin in Gaa−/− mouse lysosomes. Our study identified that a defect in the degradation of glycogenin‐exposed residual glycogen in lysosomes was the fundamental pathological mechanism of Pompe disease. Meanwhile, glycogenin‐exposed residual glycogen was absent in other glycogen storage diseases caused by cytoplasmic glycogenolysis deficiencies. In vitro, the generation of residual glycogen resulted from cytoplasmic glycogenolysis. Notably, the inhibition of glycogen phosphorylase led to a reduction in glycogenin‐exposed residual glycogen and glycophagy accumulations in cellular models of Pompe disease. Therefore, the lysosomal hydrolysis pathway played a crucial role in the degradation of residual glycogen into glycogenin, which took place in tandem with cytoplasmic glycogenolysis. These findings may offer a novel substrate reduction therapeutic strategy for Pompe disease. © 2024 The Pathological Society of Great Britain and Ireland.

Glycophagy: An emerging target in pathology

The glycogen cargo receptor STBD1: from biology to disease targeted therapies

Myocardial glycogen dynamics: new perspectives on disease mechanisms.

Regulation and role of glycophagy in skeletal muscle energy metabolism

Methods for detection of cardiac glycogen-autophagy

Targeted glycophagy ATG8 therapy for diabetic heart disease

Golgiphagy: a novel selective autophagy to the fore

Role of Autophagy in Inherited Metabolic and Endocrine Myopathies

Glycophagy Mediated Glucose-Induced Changes of Hepatic Glycogen Metabolism Via OGT1-AKT1-FOXO1Ser238 Pathway.

Glycophagy mediated glucose-induced changes of hepatic glycogen metabolism via OGT1-AKT1-FOXO1 Ser238 pathway

Targeting selective autophagy and beyond: From underlying mechanisms to potential therapies

Targeting Autophagy to Overcome Human Diseases

Brain-Type Glycogen Phosphorylase (PYGB) in the Pathologies of Diseases: A Systematic Review

Failure of Autophagy in Pompe Disease

Defect in degradation of glycogenin‐exposed residual glycogen in lysosomes is the fundamental pathomechanism of Pompe disease

Glycogen‐binding Protein STBD1: Molecule and Role in Pathophysiology

Reticulophagy-a new target for diseases prevention and treatment

Lipophagy and Liver Disease: New Perspectives to Better Understanding and Therapy.

Glycophagy is an ancient bilaterian pathway supporting metabolic adaptation through STBD1 structural evolution

Revisiting Glycogen in Cancer: A Conspicuous and Targetable Enabler of Malignant Transformation

Decoding the molecular mechanism of selective autophagy of glycogen mediated by autophagy receptor STBD1